Hernández-Mariano José Ángel, Baltazar-Reyes Mary Carmen, Salazar-Martínez Eduardo, Cupul-Uicab Lea A
School of Public Health of Mexico/National Institute of Public Health, Cuernavaca, Morelos, 62100, Mexico.
Center for Population Health Research, National Institute of Public Health, Cuernavaca, Morelos, 62100, Mexico.
Int J Hyg Environ Health. 2022 Jan;239:113865. doi: 10.1016/j.ijheh.2021.113865. Epub 2021 Oct 23.
Experimental evidence suggests that p,p'-DDE might be involved in the development of diabetes and hypertension (HTN); however, the evidence in humans is inconclusive.
To summarize the epidemiological evidence for the association of p,p'-DDT exposure and its breakdown products with the risk of diabetes and HTN from prospective studies.
We performed a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Eligible studies (prospective) were search in PubMed, Web of Science, EBSCO, and SciELO databases (July 11, 2020). Different search algorithms were used for diabetes and HTN. Pooled odds ratios (ORs) were estimated from meta-analysis with random effects for each exposure and outcome.
A total of 23 prospective studies were included in this review, 16 assessed diabetes and seven HTN; very few measured p,p'-DDT. Exposure to p,p'-DDE was associated with a slightly increased risk of type 2 diabetes (T2D) (pooled OR = 1.44; 95%CI: 1.00, 2.07; p = 0.049) and HTN (pooled OR = 1.21; 95%CI: 1.07, 1.38). Dose-response meta-analysis suggested a non-linear relation between p,p'-DDE and T2D. Exposure to p,p'-DDE was not associated with gestational diabetes (pooled OR = 1.01; 95%CI: 0.94, 1.09); similarly, p,p'-DDT was not associated with T2D (pooled OR = 1.03; 95%CI: 0.79, 1.35).
Evidence from prospective studies suggests that exposure to p,p'-DDE, the main breakdown product of p,p'-DDT, might increase the risk of developing T2D; such increase may be apparent only at low levels. Exposure to p,p'-DDE may also increase the risk of having HTN; however, further evidence is required.
实验证据表明,p,p'-滴滴滴可能与糖尿病和高血压(HTN)的发生有关;然而,人体研究证据尚无定论。
总结前瞻性研究中p,p'-滴滴涕暴露及其分解产物与糖尿病和高血压风险之间关联的流行病学证据。
我们依据系统评价与Meta分析的首选报告项目(PRISMA)声明进行了系统评价和Meta分析。在PubMed、Web of Science、EBSCO和SciELO数据库(2020年7月11日)中检索符合条件的研究(前瞻性研究)。针对糖尿病和高血压使用了不同的检索算法。通过Meta分析采用随机效应模型对每种暴露和结局估计合并比值比(OR)。
本评价共纳入23项前瞻性研究,其中16项评估糖尿病,7项评估高血压;很少有研究测量p,p'-滴滴涕。暴露于p,p'-滴滴滴与2型糖尿病(T2D)风险略有增加相关(合并OR = 1.44;95%CI:1.00, 2.07;p = 0.049)以及与高血压相关(合并OR = 1.21;95%CI:1.07, 1.38)。剂量反应Meta分析表明p,p'-滴滴滴与T2D之间存在非线性关系。暴露于p,p'-滴滴滴与妊娠期糖尿病无关(合并OR = 1.01;95%CI:0.94, 1.09);同样,p,p'-滴滴涕与T2D无关(合并OR = 1.03;95%CI:0.79, 1.35)。
前瞻性研究证据表明,暴露于p,p'-滴滴涕的主要分解产物p,p'-滴滴滴可能增加患T2D的风险;这种增加可能仅在低水平时明显。暴露于p,p'-滴滴滴也可能增加患高血压的风险;然而,还需要进一步的证据。